Latest Articles

Publication Date
Post-marketing safety profile of Myfembree in approved gynecologic indications: a disproportionality analysis based on the FAERS database.

Myfembree, a fixed-dose combination of relugolix, estradiol, and norethindrone acetate, is approved for premenopausal women with heavy menstrual bleeding associated with uterine fibroids and moderate to severe pain associated with …

Published: Sept. 24, 2026, midnight
Depot medroxyprogesterone acetate and the risk for developing an intracranial meningioma.

Several investigations have reported on the increased risk of meningioma following depot medroxyprogesterone acetate (DMPA) treatment. An extensive PubMed search was conducted evaluate systematic reviews, propensity-matched studies and case-control studies …

Published: Sept. 21, 2026, midnight
Achieving Minimal-to-No Pain in Women with Endometriosis Treated with Relugolix Combination Therapy: SPIRIT Extension Trial.

Relugolix is an oral, non-peptide gonadotropin-releasing hormone receptor antagonist administered as once-daily combination therapy (relugolix-CT; 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate) to reduce endometriosis symptoms while …

Published: Sept. 5, 2026, midnight
Exploring New Treatment Strategies for Endometriosis-Narrative Review.

The pharmacological treatment of endometriosis using SPRMs requires improvement. The pure PR-agonist dienogest (DNG), a clinically established progestin, can serve as a reference compound for comparison. Its efficacy and safety …

Published: July 28, 2026, midnight
Pulmonary alveolar proteinosis diagnosed during leuprorelin acetate therapy for ovarian endometrioma: a case report.

Pulmonary alveolar proteinosis (PAP) is a rare pulmonary disorder characterized by impaired surfactant clearance due to alveolar macrophage dysfunction. Leuprorelin acetate, a gonadotropin-releasing hormone agonist, is widely used in the …

Published: July 17, 2026, midnight
Medroxyprogesterone Acetate Market Forecast 2026-2035: Growth Driven by Contraceptive Access and Hormone Therapy - News and Statistics - IndexBox

Medroxyprogesterone Acetate Market Forecast 2026-2035: Growth Driven by Contraceptive Access and Hormone Therapy - News and Statistics IndexBox

Published: July 10, 2026, 11:11 a.m.
Vitamin D3 promotes regression of endometrial implants comparable to buserelin in a rat model of endometriosis.

Buserelin, a gonadotropin-releasing hormone agonist, reduces gonadotropin and estrogen levels and is commonly used to alleviate the symptoms of endometriosis. Vitamin D3 has been reported to exhibit anti-inflammatory and pro-apoptotic …

Published: June 30, 2026, midnight
Indications and Efficacy of Progestogen-Monotherapy as Menopause Hormone Therapy: A Narrative Review.

Menopausal hormone therapy (MHT) remains the most effective treatment for vasomotor symptoms (VMS) and other manifestations of menopause; however, its use is limited in women with contraindications to oestrogen. Progestogen …

Published: June 25, 2026, midnight
Progestin therapy in premenopausal women with incidental meningioma-a narrative review and recommendations for women's health specialists.

To review recent evidence on the association between progestin exposure and meningioma risk and to propose practical recommendations for hormonal management in women requiring progestin therapy.

Published: June 21, 2026, midnight
GOT1 promotes endometrial cancer progression by regulating ferroptosis through the STAT3-GPX4 axis and attenuating medroxyprogesterone acetate sensitivity - Nature

GOT1 promotes endometrial cancer progression by regulating ferroptosis through the STAT3-GPX4 axis and attenuating medroxyprogesterone acetate sensitivity Nature

Published: June 2, 2026, 3:03 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!